Match!

Senolytics and senostatics as adjuvant tumour therapy

Published on Mar 1, 2019in EBioMedicine6.68
· DOI :10.1016/j.ebiom.2019.01.056
Susan C Short28
Estimated H-index: 28
(St James's University Hospital),
Edward Fielder7
Estimated H-index: 7
(Newcastle University)
+ 1 AuthorsThomas von Zglinicki4
Estimated H-index: 4
(Newcastle University)
Abstract
Abstract Cell senescence is a driver of ageing, frailty, age-associated disease and functional decline. In oncology, tumour cell senescence may contribute to the effect of adjuvant therapies, as it blocks tumour growth. However, this is frequently incomplete, and tumour cells that recover from senescence may gain a more stem-like state with increased proliferative potential. This might be exaggerated by the induction of senescence in the surrounding niche cells. Finally, senescence will spread through bystander effects, possibly overwhelming the capacity of the immune system to ablate senescent cells. This induces a persistent system-wide senescent cell accumulation, which we hypothesize is the cause for the premature frailty, multi-morbidity and increased mortality in cancer survivors. Senolytics, drugs that selectively kill senescent cells, have been developed recently and have been proposed as second-line adjuvant tumour therapy. Similarly, by blocking accelerated senescence following therapy, senolytics might prevent and potentially even revert premature frailty in cancer survivors. Adjuvant senostatic interventions, which suppress senescence-associated bystander signalling, might also have therapeutic potential. This becomes pertinent because treatments that are senostatic in vitro (e.g. dietary restriction mimetics) persistently reduce numbers of senescent cells in vivo, i.e. act as net senolytics in immunocompetent hosts.
  • References (149)
  • Citations (6)
📖 Papers frequently viewed together
22 Citations
31 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
References149
Newest
#1Mikolaj Ogrodnik (Newcastle University)H-Index: 15
#2Yi Zhu (Mayo Clinic)H-Index: 17
Last. Diana Jurk (Newcastle University)H-Index: 25
view all 24 authors...
Summary Cellular senescence entails a stable cell-cycle arrest and a pro-inflammatory secretory phenotype, which contributes to aging and age-related diseases. Obesity is associated with increased senescent cell burden and neuropsychiatric disorders, including anxiety and depression. To investigate the role of senescence in obesity-related neuropsychiatric dysfunction, we used the INK-ATTAC mouse model, from which p16 Ink4a -expressing senescent cells can be eliminated, and senolytic drugs dasat...
16 CitationsSource
#1Paulo F. L. da Silva (Newcastle University)H-Index: 1
#2Mikolaj Ogrodnik (Newcastle University)H-Index: 15
Last. Thomas von Zglinicki (NEU: Near East University)H-Index: 4
view all 11 authors...
Senescent cells accumulate with age in multiple tissues and may cause age‐associated disease and functional decline. In vitro, senescent cells induce senescence in bystander cells. To see how important this bystander effect may be for accumulation of senescent cells in vivo, we xenotransplanted senescent cells into skeletal muscle and skin of immunocompromised NSG mice. 3 weeks after the last transplantation, mouse dermal fibroblasts and myofibres displayed multiple senescence markers in the vic...
8 CitationsSource
Cellular senescence is implicated in physiological and pathological processes spanning development, wound healing, age-related decline in organ functions and cancer. Here, we discuss cell-autonomous and non-cell-autonomous properties of senescence in the context of tumour formation and anticancer therapy, and characterize these properties, such as reprogramming into stemness, tissue remodelling and immune crosstalk, as far more dynamic than suggested by the common view of senescence as an irreve...
19 CitationsSource
#1Moussab Damlaj (King Saud bin Abdulaziz University for Health Sciences)H-Index: 1
#2Riad El FakihH-Index: 8
Last. Shahrukh K. Hashmi (Mayo Clinic)H-Index: 21
view all 3 authors...
Abstract Recent advancements in cancer care, coupled with early detection and an aging population have resulted in significant growth of cancer survivors. Long term follow up of such survivors is essential given the heightened risk for development of late effects such as secondary neoplasms, cardiovascular disease or psychosocial dysfunction among others. As more patients with hematologic malignancies are cured or managed over protracted periods of time, awareness of such issues is paramount for...
8 CitationsSource
#1Vassilios Myrianthopoulos (UoA: National and Kapodistrian University of Athens)H-Index: 16
#2Konstantinos Evangelou (UoI: University of Ioannina)H-Index: 21
Last. Vassilis G. GorgoulisH-Index: 50
view all 10 authors...
Abstract Cellular senescence is a stress response mechanism ensuring homeostasis. Its temporal activation during embryonic development or normal adult life is linked with beneficial properties. In contrast, persistent (chronic) senescence seems to exert detrimental effects fostering aging and age-related disorders, such as cancer. Due to the lack of a reliable marker able to detect senescence in vivo, its precise impact in age-related diseases is to a large extent still undetermined. A novel rea...
11 CitationsSource
#1Marcus Ruscetti (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 1
#2Josef Leibold (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 6
Last. Scott W. Lowe (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 119
view all 20 authors...
Molecularly targeted therapies aim to obstruct cell autonomous programs required for tumor growth. We show that mitogen-activated protein kinase (MAPK) and cyclin-dependent kinase 4/6 inhibitors act in combination to suppress the proliferation of KRAS-mutant lung cancer cells while simultaneously provoking a natural killer (NK) cell surveillance program leading to tumor cell death. The drug combination, but neither agent alone, promotes retinoblastoma (RB) protein-mediated cellular senescence an...
19 CitationsSource
#1Maja Milanovic (Humboldt University of Berlin)H-Index: 5
#2Yong Yu (MDC: Max Delbrück Center for Molecular Medicine)H-Index: 7
Last. Clemens A. SchmittH-Index: 31
view all 3 authors...
Activated oncogenes or anticancer therapies evoke senescent cell-cycle arrest in (pre-)malignant cells, thereby interrupting tumor formation or progression. Physiologically, cellular senescence contributes to embryonic development and tissue regeneration. These observations and the overlap of numerous gene products in senescence and stem cell signaling prompted investigations into whether epigenetic establishment of the senescent state may concomitantly reprogram the cell into a latent stem-like...
9 CitationsSource
#1Freddie Ian Bray (IARC: International Agency for Research on Cancer)H-Index: 91
#2Jacques Ferlay (IARC: International Agency for Research on Cancer)H-Index: 65
Last. Ahmedin Jemal (ACS: American Cancer Society)H-Index: 110
view all 6 authors...
This article provides a status report on the global burden of cancer worldwide using the GLOBOCAN 2018 estimates of cancer incidence and mortality produced by the International Agency for Research on Cancer, with a focus on geographic variability across 20 world regions. There will be an estimated 18.1 million new cancer cases (17.0 million excluding nonmelanoma skin cancer) and 9.6 million cancer deaths (9.5 million excluding nonmelanoma skin cancer) in 2018. In both sexes combined, lung cancer...
3,723 CitationsSource
#2Marianna Skolnaja (Tallinn University of Technology)H-Index: 2
Last. Manlio Vinciguerra (UCL: University College London)H-Index: 36
view all 8 authors...
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death, which develops in the context of fibrosis and cirrhosis caused by chronic inflammation, in turn due to non-alcoholic fatty liver disease (NAFLD), alcohol consumption and/or hepatitis viral infection. An increased number of senescent cells are associated with age-related tissue degeneration during NAFLD-induced HCC, or during chemotherapeutic treatment. Senolytic agents target selectively senescent cells. A combination of ...
7 CitationsSource
#1Matthew J. Yousefzadeh (Scripps Research Institute)H-Index: 6
#2Yi Zhu (Mayo Clinic)H-Index: 17
Last. Laura J. Niedernhofer (Scripps Research Institute)H-Index: 47
view all 22 authors...
Abstract Background Senescence is a tumor suppressor mechanism activated in stressed cells to prevent replication of damaged DNA. Senescent cells have been demonstrated to play a causal role in driving aging and age-related diseases using genetic and pharmacologic approaches. We previously demonstrated that the combination of dasatinib and the flavonoid quercetin is a potent senolytic improving numerous age-related conditions including frailty, osteoporosis and cardiovascular disease. The goal o...
36 CitationsSource
Cited By6
Newest
#1Masum Rahman (Mayo Clinic)
#2Ian Olson (Mayo Clinic)
Last. Mark A. Schroeder (Mayo Clinic)H-Index: 34
view all 21 authors...
Despite decades of research and numerous basic science advances, there have only marginal gains in improving glioblastoma multiforme survival. Therefore, new ideas and approaches for treating this aggressive disease are essential to drive progress forward. Conventional therapies, such as radiation and Temozolomide (TMZ), function to cause oxidative stress and DNA damage yielding a senescent-like state of replicative arrest in susceptible cells. However, increasing evidence demonstrates malignant...
Source
#1Nathan Basisty (Buck Institute for Research on Aging)H-Index: 6
#2Abhijit Kale (Buck Institute for Research on Aging)H-Index: 7
Last. Birgit Schilling (Buck Institute for Research on Aging)H-Index: 40
view all 5 authors...
Introduction: Cellular senescence is a rapidly growing field with potential relevance for the treatment of multiple human diseases. In the last decade, cellular senescence and the senescence-associ...
Source
#1Kristina Kirschner (Glas.: University of Glasgow)H-Index: 14
#2Nattaphong Rattanavirotkul (MU: Mahidol University)H-Index: 3
Last. Tamir Chandra (Edin.: University of Edinburgh)H-Index: 20
view all 4 authors...
Senescence is a tumour suppressor mechanism which is cell-intrinsically activated in the context of cellular stress. Senescence can further be propagated to neighbouring cells, a process called secondary senescence induction. Secondary senescence was initially shown as a paracrine response to the secretion of cytokines from primary senescent cells. More recently, juxtacrine Notch signalling has been implicated in mediating secondary senescence induction. Primary and secondary senescent induction...
Source
#1Nesrine Mabrouk (PSL Research University)H-Index: 1
#1Nesrine Mabrouk (University of Burgundy)H-Index: 2
Last. Catherine Paul (PSL Research University)H-Index: 19
view all 6 authors...
Cellular senescence is a cell state involved in both physiological and pathological processes such as age-related diseases and cancer. While the mechanism of senescence is now well known, its role in tumorigenesis still remains very controversial. The positive and negative effects of senescence on tumorigenesis depend largely on the diversity of the senescent phenotypes and, more precisely, on the senescence-associated secretory phenotype (SASP). In this review, we discuss the modulatory effect ...
1 CitationsSource
#1Joshua B. Rubin (WashU: Washington University in St. Louis)H-Index: 46
#2Joseph S. Lagas (WashU: Washington University in St. Louis)H-Index: 1
Last. P. I. Imoukhuede (WashU: Washington University in St. Louis)H-Index: 14
view all 11 authors...
We now know that cancer is many different diseases, with great variation even within a single histological subtype. With the current emphasis on developing personalized approaches to cancer treatment, it is astonishing that we have not yet systematically incorporated the biology of sex differences into our paradigms for laboratory and clinical cancer research. While some sex differences in cancer arise through the actions of circulating sex hormones, other sex differences are independent of estr...
1 CitationsSource
#1Amanpreet Kaur (University of Leicester)H-Index: 1
#2Salvador Macip (Open University of Catalonia)H-Index: 15
Last. Cordula M. Stover (University of Leicester)H-Index: 24
view all 3 authors...
The average human life expectancy has increased globally, and continues to rise, owing to the substantive progress made in healthcare, medicine, sanitation, housing and education. This ultimately enriches society with a greater proportion of elderly people. Sustaining a healthy aged population is key to diminish the societal and economic impact of age-related infirmities. This is especially challenging because tissue function, and thus wellbeing, naturally progressively decline as humans age. Wi...
1 CitationsSource
#1Tareq Saleh (HU: Hashemite University)H-Index: 2
#1Tareq Saleh (HU: Hashemite University)H-Index: 2
Last. David A. Gewirtz (VCU: Virginia Commonwealth University)H-Index: 43
view all 8 authors...
For the past two decades, cellular senescence has been recognized as a central component of the tumor cell response to chemotherapy and radiation. Traditionally, this form of senescence, termed Therapy-Induced Senescence (TIS), was linked to extensive nuclear damage precipitated by classical genotoxic chemotherapy. However, a number of other forms of therapy have also been shown to induce senescence in tumor cells independently of direct genomic damage. This review attempts to provide a comprehe...
1 CitationsSource
Last. Xue Lei (DI: Discovery Institute)H-Index: 1
view all 19 authors...
Cellular senescence is a potent tumor suppressor mechanism but also contributes to aging and aging-related diseases. Senescence is characterized by a stable cell cycle arrest and a complex proinflammatory secretome, termed the senescence-associated secretory phenotype (SASP). We recently discovered that cytoplasmic chromatin fragments (CCFs), extruded from the nucleus of senescent cells, trigger the SASP through activation of the innate immunity cytosolic DNA sensing cGAS-STING pathway. However,...
5 CitationsSource
#1Jacqueline Brinkman (U of C: University of Chicago)H-Index: 1
#2Yue Liu (U of C: University of Chicago)H-Index: 2
view all 3 authors...
Abstract For decades genotoxic therapy has been a mainstay in the treatment of cancer, based on the understanding that the deregulated growth and genomic instability that drive malignancy also confer a shared vulnerability. Although chemotherapy and radiation can be curative, only a fraction of patients benefit, while nearly all are subjected to the harmful side-effects. Drug repurposing, defined here as retooling existing drugs and compounds as chemo or radiosensitizers, offers an attractive ro...
Source
#1Ezio Laconi (University of Cagliari)H-Index: 23
#2Fabio Marongiu (University of Cagliari)H-Index: 19
Last. James DeGregori (Anschutz Medical Campus)H-Index: 49
view all 3 authors...
Why do we get cancer mostly when we are old? According to current paradigms, the answer is simple: mutations accumulate in our tissues throughout life, and some of these mutations contribute to cancers. Although mutations are necessary for cancer development, a number of studies shed light on roles for ageing and exposure-dependent changes in tissue landscapes that determine the impact of oncogenic mutations on cellular fitness, placing carcinogenesis into an evolutionary framework. Natural sele...
2 CitationsSource